Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.9% during the 1st quarter, HoldingsChannel reports. The firm owned 31,870 shares of the biopharmaceutical company’s stock after selling 1,650 shares during the period. Segall Bryant & Hamill LLC’s holdings in Madrigal Pharmaceuticals were worth $16,683,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Hsbc Holdings PLC acquired a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at $309,000. Qube Research & Technologies Ltd acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth $1,163,000. Sei Investments Co. boosted its holdings in shares of Madrigal Pharmaceuticals by 73.6% in the second quarter. Sei Investments Co. now owns 17,542 shares of the biopharmaceutical company’s stock valued at $5,309,000 after acquiring an additional 7,438 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Madrigal Pharmaceuticals by 2.1% in the second quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company’s stock valued at $7,087,000 after acquiring an additional 471 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in shares of Madrigal Pharmaceuticals during the second quarter worth about $418,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Trading Down 5.2%

Shares of MDGL opened at $467.32 on Friday. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average is $516.48 and its two-hundred day moving average is $499.05. Madrigal Pharmaceuticals, Inc. has a twelve month low of $290.00 and a twelve month high of $615.00. The firm has a market capitalization of $10.78 billion, a P/E ratio of -36.25 and a beta of -1.05.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. The company had revenue of $364.25 million during the quarter, compared to the consensus estimate of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 55.04%. The company’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same period last year, the firm earned ($1.90) EPS. On average, research analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

MDGL has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday. Piper Sandler reiterated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Truist Financial lifted their price target on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Wells Fargo & Company initiated coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 price objective on the stock. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $688.20.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, insider David Soergel sold 1,042 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the sale, the insider owned 10,033 shares of the company’s stock, valued at approximately $4,973,759.42. This represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the completion of the transaction, the director owned 22,015 shares of the company’s stock, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,568 shares of company stock valued at $3,880,711 over the last ninety days. 17.60% of the stock is currently owned by company insiders.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.